MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BRTX had -$952,807 decrease in cash & cash equivalents over the period. -$2,901,137 in free cash flow.

Cash Flow Overview

Change in Cash
-$952,807
Free Cash flow
-$2,901,137

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Net loss
-3,038,277 -7,996,062
Depreciation and amortization
52,620 104,529
Dividend and interest income
59,336 176,542
Stock-based compensation
399,932 2,477,834
Change in fair value of warrant liabilities
612,064 -59,528
Accounts receivable
-1,600 -173,400
Prepaid expenses and other current assets
2,366 -21,359
Lease liability
-0
Non-cash lease expense
-0
Deferred revenue
-0
Accounts payable
230,209 126,861
Gain on exchange of warrants
-0
Accrued expenses and other current liabilities
126,545 -263,560
Net cash used in operating activities
-2,901,137 -5,472,653
Sale of marketable securities
2,548,105 6,664,238
Purchase of marketable securities
550,467 2,128,680
Purchases of equipment
0 36,400
Net cash provided by (used in) investing activities
1,997,638 4,499,158
Proceeds from issuance of common stock in at-the-market offering
0 2,011,250
Payment of issuance costs
0 72,805
Proceeds from exchange and issuance of warrants, net
-0
Exercise of stock options
0 42,411
Deferred offering costs
49,308 0
Net cash provided by financing activities
-49,308 1,980,856
Net increase in cash and cash equivalents
-952,807 1,007,361
Cash and cash equivalents at beginning of period
547,890 -
Cash and cash equivalents at end of period
602,444 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

BioRestorative Therapies, Inc. (BRTX)

BioRestorative Therapies, Inc. (BRTX)